|
Published by: Business Insights
Published: Aug. 25, 2003 - 200 Pages
Table of Contents
Executive Summary
- Overview of the global therapeutic proteins market
- Erythropoietins
- Interferons
- Insulins
- Monoclonal antibodies
- Blood factors
- Colony stimulating factors
- Growth hormones
- Interleukins
- Growth factors
- Therapeutic vaccines
- Other therapeutic proteins
Chapter 1 Overview of the global
- therapeutic proteins market
- Summary
- Introduction
- Protein classification
- Segmentation of the global therapeutic protein market
- Major influencers of therapeutic protein market growth
- Drug delivery challenges
- Injectable systems
- Pulmonary delivery
- Transdermal technologies
- Oral delivery
- Manufacturing capacity shortfall
- Why is there a capacity shortfall?
- Overcoming manufacturing issues
- Biogeneric competition
- Will gene therapy supercede therapeutic proteins?
Chapter 2 Erythropoietins
- Summary
- Class overview
- Mechanism of action
- Global sales
- Analysis of leading products
- Procrit/Eprex (epoetin alpha)
- Epogen (epoetin alpha) and Aranesp (darbepoetin alpha)
- NeoRecormon/Epogin (epoetin beta)
- Late stage R&D activity
- Hemolink (hemoglobin raffimer)
Chapter 3 Interferons
- Summary
- Class overview
- Mechanism of action
- Global sales
- Analysis of leading products
- Intron family
- Intron A (interferon alpha-2b)
- PEG Intron (peg interferon alpha-2b)
- Rebetol (ribavirin)
- Rebetron (interferon alpha-2b + ribavirin)
- Roferon-A (interferon alpha-2a) and Pegasys (pegylated interferon alpha-2a)
- Avonex (interferon beta-1a)
- Rebif (interferon beta)
- Late stage R&D activity
Chapter 4 Insulins
- Summary
- Class overview
- Mechanism of action
- Global sales
- Analysis of leading products
- Novolin (insulin)
- Humulin (insulin)
- Humalog (insulin lispro)
- Lantus (glargine insulin)
- Late stage R&D activity
- NN304 (insulin Detemir)
- AERx iDMS
- Exubera (inhaled insulin)
Chapter 5 Monoclonal antibodies
- Summary
- Class overview
- Mechanism of action
- Global sales
- Analysis of leading products
- Mabthera/Rituxan (rituxumab)
- Remicade (infliximab)
- Herceptin (trastuzumab)
- Humira (adalimumab)
- Late stage R&D activity
- Xolair (omalizumab)
- Bexxar (tositumomab)
- Raptiva (efalizumab)
- Erbitux/IMC-C225 (cetuximab)
Chapter 6 Blood factors
- Summary
- Class overview
- Mechanism of action
- Global sales
- Analysis of leading products
- Activase/TNKase (alteplase/tenecteplase)
- NovoSeven (rh factor VIIa)
- Late stage R&D activity
Chapter 7 Colony stimulating factors
- Summary
- Class overview
- Mechanism of action
- Global sales
- Analysis of leading products
- Neupogen (filgrastim)
- Neulasta (pegfilgrastim)
- Late stage R&D activity
Chapter 8 Growth hormones
- Summary
- Class overview
- Mechanism of action
- Global sales
- Analysis of leading products
- Genotropin (somatropin)
- Nutropin/Protropin (somatropin/somatrem)
- Norditropin/Norditropin SimpleXx (r-Somatropin)
- Saizen (somatropin)
- Late stage R&D activity
- Serostim (somatropin)
Chapter 9 Interleukins
- Summary
- Class overview
- Mechanism of action
- Global sales
- Analysis of leading products
- Proleukin (interleukin-2)
- Late stage R&D activity
Chapter 10 Growth factors
- Summary
- Class overview
- Mechanism of action
- Global sales
- Analysis of leading products
- Regranex (beclapermin)
- Fiblast (trafermin)
- Late stage R&D activity
- Stemgen (ancetism)
- Keratinocyte growth factor
Chapter 11 Therapeutic vaccines
- Summary
- Class overview
- Mechanism of action
- Global sales
- Analysis of leading products
- Melacine (theraccine)
- M-Vax
- OncoVax
- Late stage R&D activity
- Cancer
- HIV
- Barriers to HIV vaccine development
Chapter 12 Other therapeutic proteins
- Summary
- Class overview
- Global sales
- Analysis of leading products
- Enbrel (etanercept)
- Cerezyme (imiglucerase)
- Xigris (drotrecogin alpha)
- Late stage R&D activity
- Index
AbstractThe management report, 'The Therapeutic Proteins Outlook to 2007: An analysis of leading products and late-stage pipeline developments' is a timely global market assessment of the ten major therapeutic protein classes. This report provides product forecasts to 2007, and defines the driving forces that will impact the therapeutic proteins market, allowing you to determine how the future competitive landscape will affect your company. The therapeutic proteins market is thriving, generating global sales of $33,340m in 2002, a 24% increase upon 2001 sales of $26,881m. Understand the key growth areas and find out whether interferons will continue to be the major driver of overall growth in the next five years. This report provides a single source of key product and sales analysis, summarizing changing competitive dynamics and developments to the market therapeutic proteins. Use this timely analysis to forecast the future with confidence within this market and benchmark your product strategies by therapeutic class against your key competitors.
Get Full Details About This Report >>
|
